DVA · DaVita Inc.
$235.44
+1.33% last session
End-of-day data · updated 2026-07-28
Market cap
$15B
Enterprise value
$30B
Trailing P/E
22.8
Forward P/E
13.7
Dividend yield
—
Beta
0.88
Avg volume
1M
Employees
78K
2D change
—
5D change
0.87%
10D change
-0.28%
30D change
8.88%
60D change
21.58%
MTD change
3.63%
YTD change
108.00%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DVA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-14
Latest call per bank · past 12 months
UBS
Buy$270
+14.7% vs priceBarclays
Equal-Weight$218
-7.4% vs priceDeutsche Bank
Buy$220
-6.6% vs priceBank of America
Underperform$140
-40.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-14 | Truist Securities | Maintains | Hold | $205 → $250 |
| 2026-07-10 | UBS | Maintains | Buy | $235 → $270 |
| 2026-07-09 | Barclays | Maintains | Equal-Weight | $194 → $218 |
| 2026-05-11 | TD Cowen | Maintains | Hold | $144 → $201 |
| 2026-05-08 | Truist Securities | Maintains | Hold | $158 → $205 |
| 2026-05-08 | Barclays | Maintains | Equal-Weight | $158 → $194 |
| 2026-05-07 | UBS | Maintains | Buy | $190 → $235 |
| 2026-05-06 | Deutsche Bank | Upgrade | Hold → Buy | $126 → $220 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 68 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 12.2% above the 50-day MA ($213.49).
- Price vs 200-day MA: Trading 55.1% above the 200-day MA ($154.38).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.92) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($239.46).
DVA Price Chart
Loading chart for DVA…
Fundamentals
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
More in Medical Care Facilities
HCA
HCA Healthcare, Inc.
$86B -16.3% YTD
THC
Tenet Healthcare Corporation
$21B 22.5% YTD
FMS
Fresenius Medical Care AG
$13B 8.6% YTD
EHC
Encompass Health Corporation
$11B 7.9% YTD
UHS
Universal Health Services, Inc.
$10B -26.8% YTD
ENSG
The Ensign Group, Inc.
$10B 2.3% YTD
CHE
Chemed Corp
$7B 19.4% YTD
PACS
PACS Group, Inc.
$7B 22.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.